# NAD+ References: The Cited Studies and Reviews

> NAD+ references: every study cited across this digest, with DOIs and PubMed links — the NMN and NR human trials, the CD38 and mechanism reviews, the IV pilot, and 2024-2026 reviews.

Every quantitative claim on this site maps to a study below, with a DOI or PubMed link to the source.

## How to read this list

Every numbered marker across the digest resolves to one entry here. Where a claim is quantitative — a dose, a percentage rise in blood NAD+, an n-value, a clearance time — the number points to the study that measured it. Human trials, mechanism reviews, and the 2024-2026 literature are all listed together; each entry carries a DOI or a PubMed identifier so the source can be checked directly.

## References

[1] Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
[2] Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/
[3] Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. https://pubmed.ncbi.nlm.nih.gov/36482258/
[4] Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772. https://pubmed.ncbi.nlm.nih.gov/31278280/
[5] Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. https://pubmed.ncbi.nlm.nih.gov/33353981/
[6] Hou Y, Wei Y, Lautrup S, et al. NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING. Proc Natl Acad Sci USA. 2021;118(37):e2011226118. https://pubmed.ncbi.nlm.nih.gov/34497121/
[7] Grant R, et al. Intravenous Administration of Nicotinamide Adenine Dinucleotide Improves Cognitive Performance in Human Subjects: Implications for Clinical Populations. Arch Phys Med Rehabil. 2021;102(10):e84-e85. https://doi.org/10.1016/j.apmr.2021.07.585
[8] Pérez MJ, Baden P, Deleidi M. Progresses in both basic research and clinical trials of NAD+ in Parkinson's disease. Mech Ageing Dev. 2021;197:111499. https://pubmed.ncbi.nlm.nih.gov/33989633/
[9] Migliavacca E, Tay SKH, Patel HP, et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat Commun. 2019;10(1):5808. https://pubmed.ncbi.nlm.nih.gov/31862890/
[10] Agerholm M, Dall M, Jensen BAH, et al. Perturbations of NAD+ salvage systems impact mitochondrial function and energy homeostasis in mouse myoblasts and intact skeletal muscle. Am J Physiol Endocrinol Metab. 2018;314(4):E377-E395. https://pubmed.ncbi.nlm.nih.gov/29208611/
[11] Zhu Y, Xu P, Huang X, et al. From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases. Front Pharmacol. 2022;13:920113. https://pubmed.ncbi.nlm.nih.gov/35903330/
[12] Tempel W, Rabeh WM, Bogan KL, et al. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007;5(10):e263. https://pubmed.ncbi.nlm.nih.gov/17914902/
[13] Bohr VA. Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage. Aging Cell. 2026;e70319. https://pubmed.ncbi.nlm.nih.gov/41436848/
[14] Wu CY, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025;103633. https://pubmed.ncbi.nlm.nih.gov/41357333/
[21] Vinten KT, Trętowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/41083806/

---

The NAD+ literature read like an order book — the coenzyme and its precursors NMN and NR each listed apart, the blood-NAD+ the trials actually moved quoted to source, and the rapidly-cleared IV route flagged as the weak-data listing; no clinic behind this desk and nothing here ordered, infused, dispensed, or sold.